viru
famili
flavivirida
encompass
sever
virus
includ
emerg
virus
caus
widespread
morbid
mortal
throughout
world
member
viru
famili
positivestrand
rna
virus
replic
genom
close
associ
reorgan
intracellular
host
cell
membran
compart
evolutionarili
conserv
strategi
facilit
effici
viral
genom
replic
contribut
evas
host
cell
cytosol
defens
mechan
previous
describ
identif
smallcompound
inhibitor
exert
potent
antivir
activ
broad
rang
coronavirus
target
membranebound
viral
rna
replic
analyz
antivir
spectrum
inhibitor
assess
inhibitori
potenti
sever
member
flavivirida
famili
includ
reemerg
zika
viru
zikv
show
zikv
strongli
affect
timeofaddit
experi
reveal
act
postentri
phase
zikv
life
cycl
combin
regimen
togeth
ribavirin
rbv
interferon
alpha
increas
extent
viral
inhibit
ultrastructur
electron
microscopi
studi
reveal
sever
alter
zikvinduc
intracellular
replic
compart
upon
infect
cell
importantli
antivir
activ
demonstr
sever
member
flavivirida
famili
tempt
specul
exert
broad
antivir
activ
sever
positivestrand
rna
virus
via
similar
mechan
therebi
repres
attract
candid
develop
panvir
inhibitor
chronic
infect
million
individu
worldwid
risk
develop
liver
cirrhosi
hepatocellular
carcinoma
genu
flaviviru
encompass
speci
compris
number
vectorborn
zoonot
agent
respons
acut
selflimit
diseas
case
lead
sever
symptom
vascular
leakag
hemorrhag
enceph
mening
observ
zika
viru
zikv
recent
spread
throughout
south
central
america
caribbean
sever
flavivirus
consid
emerg
reemerg
pathogen
rapidli
becom
endem
therebi
lead
seriou
shortor
longterm
health
consequ
hepacivirus
flavivirus
therefor
major
human
health
concern
newli
propos
genu
pegiviru
well
genu
pestiviru
mainli
compris
viru
speci
veterinari
relev
caus
gastrointestin
respiratori
reproduct
diseas
anim
associ
major
econom
loss
except
hcv
intervent
strategi
member
famili
flavivirida
limit
emphas
need
develop
effect
reliabl
drug
vaccin
especi
context
newli
emerg
reemerg
viral
infect
member
flavivirida
famili
share
highli
similar
genom
organ
replic
strategi
follow
attach
surfac
host
cell
bind
cellular
entri
receptor
viral
particl
intern
via
endocyt
rout
incom
genom
releas
cytosol
singl
open
read
frame
orf
encod
structur
protein
compos
viral
particl
capsidcor
prm
envelop
glycoprotein
nonstructur
protein
primarili
form
viral
replicas
complex
ensur
polyprotein
process
membran
reorgan
rna
synthesi
function
upon
translat
viral
replicas
insert
endoplasm
reticulum
membran
orchestr
establish
replic
organel
organel
provid
privileg
membraneprotect
site
viral
rna
synthesi
close
associ
given
virusinduc
membran
remodel
conserv
mechan
among
virtual
positivesens
rna
virus
repres
attract
target
develop
panvir
inhibitor
effect
wide
rang
virus
recent
screen
aim
identifi
antihuman
coronaviru
compound
result
identif
potent
inhibitor
effici
abolish
plaqu
format
compound
shown
act
earli
postentri
stage
coronaviru
replic
target
membranebound
viral
rna
synthesi
moreov
strongli
prevent
format
typic
perinuclear
doubl
membran
vesicl
dmv
cluster
studi
lundin
et
al
extend
initi
find
mechan
inhibit
replic
demonstr
potent
pancoronaviru
antivir
activ
inde
inhibit
broad
rang
coronavirus
sever
phylogenet
lineag
alpha
beta
gammacoronavirus
includ
murin
hepat
viru
mhv
type
felin
coronaviru
fcov
avian
infecti
bronchiti
viru
ibv
well
highli
pathogen
human
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
furthermor
recent
report
impair
replic
virus
coronavirina
subfamili
also
member
torovirina
subfamili
white
beam
viru
wbv
genu
bafiniviru
equin
toroviru
etov
genu
toroviru
well
porcin
reproduct
respiratori
syndrom
viru
prrsv
equin
arter
viru
eav
repres
arterivirus
evalu
potenti
inhibit
replic
member
famili
flavivirida
show
effici
impair
replic
zikv
yellow
fever
viru
yfv
japanes
enceph
viru
jev
west
nile
viru
wnv
well
certain
extent
usutu
viru
usuv
wesselsbron
viru
wessv
hcv
bovin
viral
diarrhea
viru
bvdv
collect
studi
indic
broad
antivir
activ
wide
rang
nidovirida
flavivirida
lineag
suggest
interf
conserv
mechan
membran
rearrang
biogenesi
replic
organel
could
repres
novel
target
develop
antivir
drug
combat
positivesens
rna
viru
infect
inhibit
zikv
dosedepend
manner
given
previou
find
smallcompound
inhibitor
may
interfer
conserv
featur
virusinduc
membran
remodel
hypothes
might
addit
coronavirus
arterivirus
impair
replic
virus
belong
famili
flavivirida
zikv
test
hypothesi
cell
infect
zikv
viru
replic
assess
h
postinfect
pi
measur
intracellular
level
e
protein
flow
cytometri
percentag
cell
harbor
replic
viru
reflect
e
protein
express
significantli
decreas
dosedepend
manner
upon
treatment
cell
h
pi
fig
titrat
viral
supernat
confirm
signific
inhibit
zikv
infect
upon
treatment
time
point
ie
h
pi
inhibitori
concentr
ic
respect
tabl
inde
suffici
reduc
viral
titer
order
magnitud
higher
concentr
reduc
viral
titer
order
magnitud
fig
flow
cytometr
analysi
reveal
cytotox
effect
concentr
indic
fig
determin
upon
applic
fixabl
aqua
dead
cell
stain
kit
result
confirm
upon
assess
cytotox
use
commerci
avail
kit
fig
howev
similar
previous
report
concentr
mildli
affect
cell
prolifer
fig
see
also
fig
supplement
materi
suggest
observ
antivir
effect
concentr
slightli
overestim
order
determin
step
viral
replic
cycl
affect
perform
timeofaddit
experi
exclud
possibl
direct
effect
viral
particl
eg
disrupt
viral
envelop
interfer
virion
stabil
preincub
zikv
increas
concentr
subsequ
assess
remain
infect
titrat
show
preincub
affect
zikv
infect
fig
next
ad
cell
differ
time
preor
postinfect
effect
viral
replic
infect
determin
titrat
viral
supernat
interestingli
also
display
antivir
activ
ad
sever
hour
postinfect
suggest
effect
postentri
stage
zikv
life
cycl
fig
collect
data
reveal
significantli
inhibit
zikv
dosedepend
manner
like
impair
critic
postentri
step
zikv
life
cycl
inhibit
sever
member
famili
flavivirida
next
assess
whether
display
broad
antivir
effect
replic
flavivirida
member
end
test
sensit
differ
flavivirus
includ
jev
yfv
wnv
usuv
wessv
well
hepaciviru
hcv
two
repres
pestiviru
bvdv
biotyp
cytopathogen
cp
noncytopathogen
ncp
bovin
viral
diarrhea
pestiviru
pair
cell
treat
increas
concentr
infect
intracellular
level
flaviviru
e
protein
marker
viral
replic
assess
flow
cytometri
moreov
viral
titer
supernat
determin
tissu
cultur
infect
dose
tcid
titrat
show
jev
yfv
replic
fig
c
infect
fig
tabl
slightli
higher
concentr
necessari
significantli
inhibit
usuv
fig
h
wessv
fig
j
ic
tabl
analyz
antivir
effect
hepaciviru
hcv
luciferaseencod
report
viru
use
virusmedi
intracellular
luciferas
express
measur
marker
viral
replic
furthermor
rule
possibl
impact
luciferas
report
activ
nonreport
hcv
construct
hcv
employ
quantit
realtim
pcr
qrtpcr
analysi
hcv
rna
level
perform
fig
addit
viral
supernat
infect
cell
harvest
use
inocul
naiv
target
cell
latter
lyse
luciferas
report
activ
determin
infect
similar
find
wnv
usuv
nonradioact
cytotox
assay
promega
well
viabil
assay
prolifer
multitoxfluor
multiplex
cytotox
assay
promega
perform
determin
cytotox
effect
vero
cell
h
posttreat
e
evalu
direct
effect
viral
stabil
zikv
dmem
incub
h
room
temperatur
differ
concentr
viral
titer
determin
number
tcid
per
millilit
f
timeofaddit
assay
perform
analyz
effect
earli
viruscel
interact
variou
concentr
ad
specif
time
point
rel
time
infect
zikv
cell
cultur
supernat
collect
h
pi
measur
viru
releas
result
repres
mean
bar
sd
n
dot
line
indic
limit
detect
nd
detect
p
valu
determin
anova
follow
dunnett
multiplecomparison
test
p
p
p
p
ns
signific
concentr
led
signific
reduct
viral
replic
well
infect
fig
b
howev
bromid
mtt
cell
prolifer
assay
indic
cell
use
infect
affect
concentr
fig
nevertheless
cytotox
concentr
cc
valu
higher
ic
tabl
reveal
antivir
effect
hcv
could
distinguish
effect
cell
viabil
nevertheless
care
interpret
data
still
requir
antivir
effect
display
may
overestim
context
hcv
infect
two
biotyp
bvdv
strain
suwa
test
suscept
treatment
viral
rna
level
determin
qrtpcr
correl
viral
replic
viral
titer
supernat
assess
titrat
similar
find
hcv
concentr
necessari
significantli
reduc
viral
replic
cp
bvdv
strain
suwa
bvdv
suwacp
fig
ncp
bvdv
strain
suwa
bvdv
suwancp
fig
respect
viral
titer
significantli
reduc
upon
treatment
bvdv
suwacp
fig
ic
tabl
wherea
least
necessari
significantli
reduc
infect
bvdv
suwancp
ic
fig
tabl
note
even
though
cellular
toxic
result
incub
concentr
indic
could
measur
cell
prolifer
affect
concentr
describ
fig
tabl
collect
data
show
inhibit
broad
rang
flavivirida
member
includ
jev
yfv
wnv
usuv
wessv
limit
extent
hcv
bvdv
combin
treatment
regimen
enhanc
antivir
activ
treatment
option
member
famili
flavivirida
remain
limit
despit
recent
success
regard
treatment
hcv
infect
develop
directact
antivir
daa
recent
zikv
epidem
underscor
import
effect
viral
inhibitor
applic
rapidli
control
outbreak
emerg
virus
ribavirin
rbv
interferon
alpha
employ
welldocu
antivir
activ
sever
rna
virus
therefor
evalu
antivir
potenti
combin
regimen
togeth
rbv
zikv
end
cell
treat
either
rbv
alon
two
drugcombin
subsequ
infect
h
viral
titer
supernat
determin
tcid
assay
singl
treatment
suffici
significantli
reduc
viral
titer
fig
singl
treatment
gml
rbv
moder
reduc
viral
titer
wherea
increas
concentr
gml
gml
correl
significantli
reduc
viral
titer
supernat
fig
howev
high
rbv
concentr
gml
gml
also
impact
cell
viabil
fig
effect
zikv
dose
iu
fig
effect
cell
viabil
fig
combin
treatment
either
gml
rbv
improv
antivir
effect
howev
addit
least
gml
rbv
combin
low
concentr
increas
overal
antivir
effect
fig
g
furthermor
combin
togeth
gml
rbv
reduc
viral
titer
order
magnitud
compar
untreat
control
fig
g
similarli
combin
treatment
dose
iu
togeth
potenti
antivir
effect
fig
g
particular
combin
iu
result
viral
titer
reduc
least
order
magnitud
without
impact
cell
prolifer
fig
combin
treatment
rbv
dose
iu
gml
rbv
increas
antivir
effect
zikv
compar
either
singl
treatment
fig
analysi
drug
combin
rbv
concentr
rang
concentr
drug
caus
partial
inhibit
replic
point
addit
antivir
effect
two
compound
indic
combin
index
ci
fig
combin
slight
synerg
observ
iu
concentr
indic
ci
conclus
treatment
combin
rbv
allow
use
reduc
concentr
level
zikv
replic
impair
similar
achiev
higher
concentr
rbv
alon
protect
cell
potenti
rbvinduc
cytotox
use
high
concentr
previous
report
prevent
format
typic
perinuclear
dmv
cluster
suggest
interfer
coronaviru
replic
impair
membranebound
replic
compart
biogenesi
therefor
assess
whether
antivir
effect
observ
flavivirida
specif
zikv
correl
impair
establish
zikvinduc
replic
organel
end
zikvinfect
cell
fix
h
pi
assess
fluoresc
microscopi
immunofluoresc
analysi
reveal
vast
major
cell
infect
viral
e
protein
doublestrand
rna
dsrna
effici
detect
cell
fig
left
concord
previou
result
fig
marker
viral
infect
sever
reduc
upon
treatment
therebi
confirm
potent
antivir
effect
zikv
infect
fig
right
addit
immunofluoresc
analys
select
flavivirus
jev
wnv
confirm
antivir
activ
compound
fig
furthermor
ultrastructur
zikvinduc
membran
rearrang
assess
transmiss
electron
microscopi
tem
despit
vast
major
dimethyl
sulfoxid
dmso
treat
cell
infect
fig
structur
reminisc
welldescrib
zikv
membran
replic
organel
occasion
observ
zikvinfect
cell
fig
fixat
method
cell
typespecif
determin
like
account
morpholog
differ
previous
report
zikvinduc
membran
structur
accordingli
also
report
certain
replicationassoci
structur
absent
zikvinfect
human
neural
progenitor
cell
vesicular
structur
markedli
smaller
one
observ
zikvinfect
cell
sharp
contrast
repeatedli
observ
strike
accumul
larg
vesicl
cytosol
zikvinfect
cell
treat
morpholog
chang
cellular
compart
dilat
vesicular
structur
occasion
seen
noninfect
cell
treat
fig
vesicl
notabl
larger
previous
describ
zikv
replic
organel
vesicl
least
nm
diamet
frequent
observ
unlik
repres
convent
zikvinduc
replic
organel
rather
suggest
aberr
structur
support
zikv
replic
result
treatment
continu
next
page
taken
togeth
observ
alter
intracellular
membran
organ
upon
zikv
infect
combin
treatment
associ
strong
reduct
intracellular
level
dsrna
e
protein
even
though
precis
mechan
action
remain
elucid
interfer
membran
remodel
function
membranebound
rna
replic
provid
plausibl
explan
observ
panantivir
effect
mani
member
famili
flavivirida
import
human
veterinari
pathogen
especi
sever
member
flaviviru
genu
consid
emerg
virus
defin
pathogen
exist
previous
newli
appear
popul
increas
incid
geograph
rang
success
treatment
hcv
infect
achiev
last
coupl
year
develop
highli
effect
directact
antivir
daa
therapi
moreov
favipiravir
also
known
avigan
use
yfv
wnv
infect
well
infect
caus
arenavirus
bunyavirus
alphavirus
hostdirect
compound
cyclophilin
inhibitor
inhibitor
evalu
clinic
trial
control
hcv
dengu
viru
denv
infect
respect
furthermor
prophylact
option
vaccin
develop
yfv
jev
tickborn
enceph
viru
tbev
well
denv
although
vaccin
denv
suffer
limit
efficaci
hand
vaccin
human
combat
hcv
wnv
zikv
avail
taken
togeth
avail
panel
prophylact
antivir
treatment
option
flaviviru
infect
human
anim
remain
limit
thu
emphas
need
develop
effect
reliabl
drugsvaccin
follow
screen
aim
identifi
compound
describ
potent
smallcompound
inhibitor
effici
inhibit
coronaviru
replic
recent
shown
addit
inhibit
wide
rang
viru
speci
within
famili
coronavirida
arterivirida
shown
act
earli
postentri
stage
coronaviru
replic
target
membranebound
rna
synthesi
interf
establish
virusinduc
replic
structur
importantli
mutant
abl
replic
presenc
isol
follow
sever
viru
passag
cell
escap
mutant
contain
amino
acid
substitut
nonstructur
protein
associ
resist
coronaviru
depict
data
normal
untreat
cell
viabil
bt
cell
treatment
determin
use
commerci
avail
cell
toxic
assay
cytotox
cytotox
nonradioact
cytotox
assay
promega
well
viabil
assay
prolifer
multitoxfluor
multiplex
cytotox
assay
promega
depict
data
normal
dmsotreat
cell
e
h
bt
cell
treat
h
supernat
remov
infect
bvdv
suwacp
e
f
bvdv
suwancp
g
h
h
medium
remov
medium
contain
differ
concentr
ad
e
g
cell
lyse
h
pi
intracellular
rna
extract
qrtpcr
perform
viral
replic
calcul
use
method
depict
fold
induct
compar
dmsotreat
control
cell
f
h
viral
titer
determin
serial
dilut
bt
cell
day
pi
result
repres
mean
bar
sd
n
dash
line
indic
limit
detect
p
valu
determin
anova
follow
dunnett
multiplecomparison
test
p
p
p
p
ns
signific
contain
multipl
membranespan
domain
essenti
membran
divers
event
lead
biogenesi
replic
organel
find
therebi
corrobor
critic
step
inhibit
membran
remodel
event
given
find
specul
might
offer
potenti
panvir
inhibitor
consid
replic
strategi
highli
similar
member
famili
flavivirida
positivestrand
rna
virus
inde
show
sever
member
flavivirida
effici
inhibit
virus
includ
zikv
jev
yfv
wnv
usuv
wessv
limit
extent
hcv
bvdv
moreov
combin
treatment
regimen
approv
broadact
antivir
rbv
support
antivir
effect
zikv
find
impli
effect
concentr
substanti
reduc
also
therapeut
window
improv
result
also
encourag
effort
improv
antivir
activ
assess
chemic
modif
reduc
possibl
cytotox
impact
cell
prolifer
therebi
enhanc
therapeut
rang
compartment
viral
replic
machineri
within
hostderiv
endomembran
structur
conserv
hallmark
among
positivesens
rna
virus
hypothes
provid
optim
concentr
macromolecul
coordin
regul
success
event
requir
effici
viral
replic
furthermor
compartment
protect
viral
replic
intermedi
dsrna
recognit
cytosol
pattern
recognit
receptor
elicit
first
step
host
innat
immun
respons
timeofaddit
experi
context
zikv
reveal
act
postentri
stage
presum
establish
viral
replic
cytosol
infect
cell
reminisc
suggest
mode
action
context
inhibit
subsequ
ultrastructur
analys
zikvinfect
cell
follow
treatment
reveal
predomin
appear
aberr
vacuol
cytosol
infect
cell
associ
pronounc
reduct
perinuclear
dsrna
accumul
observ
fluoresc
imag
therefor
specul
interfer
biogenesi
replic
organel
prematur
abrog
membran
divers
function
lead
function
replic
structur
howev
wherea
complet
prevent
includ
control
inoculum
remov
h
cell
wash
pb
h
pi
cell
fix
process
immunofluoresc
analysi
use
antibodi
direct
flaviviru
e
protein
dsrna
marker
zikv
replic
cell
counterstain
phalloidin
actin
dapi
nuclei
zproject
multipl
optic
section
acquir
nikon
confoc
microscop
combin
eclips
ti
invert
microscop
shown
bar
format
coronaviru
replic
organel
appear
increas
membran
prolifer
vesicl
size
zikvinduc
replic
structur
whether
suggest
either
differ
mechan
interfer
format
function
replic
complex
action
mechan
differ
outcom
remain
elucid
conclus
describ
antivir
activ
smallcompound
inhibitor
sever
member
famili
flavivirida
addit
previous
report
antivir
effect
member
famili
coronavirida
nidovirus
therefor
repres
potenti
panvir
inhibitor
could
complement
current
intervent
strategi
sever
emerg
viral
diseas
instrument
roch
mannheim
germani
describ
previous
cycl
follow
primer
probe
primer
hcv
primer
hcv
hcv
probe
tmr
primer
gapdh
primer
gapdh
gapdh
probe
lightcycl
roch
diagnost
black
hole
quencher
amount
viral
rna
rel
control
sampl
dmsotreat
cell
calcul
use
threshold
cycl
c
method
gapdh
intern
control
supernat
use
inocul
naiv
cell
seed
day
cell
per
well
dish
cell
lyse
h
pi
l
passiv
lysi
buffer
promega
per
well
assess
renilla
luciferas
activ
infect
pestiviru
replic
infect
cell
lyse
h
pi
intracellular
rna
extract
use
nucleomag
rna
kit
machereynagel
oensingen
switzerland
kingfish
flex
system
accord
manufactur
recommend
qrtpcr
perform
describ
previous
use
quantitect
probe
rtpcr
kit
qiagen
hombrechtikon
switzerland
accord
manufactur
recommend
amplif
detect
use
taqman
realtim
pcr
system
appli
biosystem
thermo
fisher
scientif
amount
viral
rna
rel
control
sampl
dmsotreat
cell
calcul
use
method
gapdh
intern
control
viral
titer
determin
serial
dilut
bt
cell
incub
co
day
bvdv
suwacp
titer
determin
microscopi
upon
quantif
cytopath
effect
cpe
bvdv
suwancp
titer
determin
upon
fixat
follow
immunoperoxidas
ipo
stain
describ
previous
use
aec
stain
kit
catalog
number
sigmaaldrich
viral
titer
calcul
express
number
tcid
per
millilit
use
method
cell
toxic
prolifer
assay
evalu
effect
cell
viabil
prolifer
well
cytotox
uninfect
cell
treat
compound
concentr
specifi
dmso
control
determin
effect
cell
viabil
vero
cell
collect
label
fixabl
aqua
dead
cell
stain
kit
thermo
fisher
scientif
min
ice
cell
wash
cold
pb
fix
flow
cytometri
analysi
posit
control
cell
death
cell
heat
min
mean
fluoresc
intens
mfi
determin
flow
cytometri
analysi
facscanto
ii
flow
cytomet
bd
bioscienc
evalu
use
flowjo
softwar
determin
cytotox
cytotox
nonradioact
cytotox
assay
catalog
number
promega
use
accord
manufactur
recommend
end
vero
cell
kindli
provid
univers
bonn
medic
centr
bonn
germani
bt
cell
seed
format
compound
ad
concentr
indic
cytotox
determin
andor
h
pi
determin
absorb
nm
use
plate
reader
versamax
molecular
devic
wokingham
uk
enspir
multilabel
reader
perkinelm
schwerzenbach
switzerland
cell
prolifer
follow
compound
treatment
determin
use
multitoxfluor
multiplex
cytotox
assay
catalog
number
promega
accord
manufactur
recommend
readout
perform
use
multilabel
reader
enspir
multilabel
reader
perkinelm
upon
excit
nm
emiss
nm
measur
effect
cell
viabil
bromid
mtt
cell
prolifer
assay
perform
h
posttreat
briefli
mtt
stock
solut
prepar
dissolv
compound
catalog
number
sigma
mgml
pb
stock
dilut
time
prewarm
complet
dmem
cell
supernat
replac
dilut
mtt
solut
lwell
cell
incub
h
cell
supernat
remov
replac
lwell
dmso
dissolv
precipit
absorb
read
nm
timeofaddit
assay
studi
effect
earli
viruscel
interact
vero
cell
seed
plate
dmem
gibco
supplement
volvol
fb
volvol
nea
gibco
volvol
penicillinstreptomycin
invitrogen
allow
reach
confluenc
overnight
subsequ
variou
concentr
ad
specif
time
point
rel
time
infect
zikv
cell
cultur
supernat
collect
h
pi
measur
viru
releas
shortli
compound
dilut
dmso
reach
desir
concentr
incub
cell
h
prior
infect
infect
period
h
infect
zikv
conduct
follow
cell
cultur
medium
remov
replac
ml
dmem
contain
zikv
dilut
moi
tcid
cell
cell
incub
h
co
next
inoculum
discard
cell
wash
prewarm
pb
cultur
medium
ad
well
addit
order
analyz
direct
effect
viru
stabil
zikv
dmem
incub
h
room
temperatur
differ
concentr
titrat
serial
dilut
vero
cell
measur
viru
infect
describ
combin
treatment
evalu
effect
combin
treatment
regimen
zikv
infect
vero
cell
seed
plate
dmem
gibco
supplement
volvol
fb
volvol
nea
gibco
volvol
penicillinstreptomycin
invitrogen
allow
reach
confluenc
overnight
cell
infect
zikv
moi
tcid
cell
co
h
inoculum
discard
cell
wash
prewarm
pb
compound
ad
variou
concentr
dilut
dmso
rbv
dilut
h
gml
dilut
h
l
either
singl
agent
combin
cell
cultur
supernat
collect
h
pi
viral
titer
determin
use
ipma
describ
calcul
number
tcid
per
millilit
cell
prolifer
upon
combin
treatment
determin
use
multitoxfluor
multiplex
cytotox
assay
promega
describ
immunofluoresc
analysi
vero
cell
seed
labtek
ii
slide
nunc
milian
geneva
switzerland
pretreat
dmso
h
cell
infect
zikv
jev
wnv
moi
tcid
cell
medium
supplement
equival
volum
dmso
control
cell
wash
pb
h
pi
incub
medium
supplement
equival
volum
dmso
addit
h
cell
fix
wtvol
pfa
permeabil
block
pb
solut
supplement
volvol
fb
wtvol
saponin
e
protein
dsrna
replic
intermedi
detect
use
antiflaviviru
group
antigen
antibodi
catalog
number
atcc
antidsrna
mab
english
scientif
consult
alexa
fluor
antimous
antibodi
use
secondari
antibodi
alexa
fluor
phalloidin
invitrogen
dapi
use
counterstain
actin
cytoskeleton
nuclei
respect
slide
mount
mowiol
mount
medium
microscopi
analysi
nikon
confoc
microscop
nikon
ag
egg
switzerland
combin
eclips
ti
invert
microscop
nikon
digit
imag
nikon
softwar
nisel
ar
use
imag
acquisit
perform
stack
least
thick
use
object
sequenti
simultan
channel
acquisit
employ
order
give
highresolut
imag
acquisit
set
perform
optim
voxel
size
automat
threshold
imag
analyz
imari
softwar
bitplan
ag
zurich
switzerland
avoid
falseposit
emiss
differ
set
includ
background
subtract
threshold
applic
gamma
correct
maxima
appli
transmiss
electron
microscopi
vero
cell
seed
plate
pretreat
dmso
h
cell
infect
zikv
moi
tcid
cell
medium
supplement
equival
volum
dmso
cell
wash
pb
h
pi
incub
medium
supplement
equival
volum
dmso
process
sampl
tem
perform
describ
et
al
shortli
cell
fix
h
pi
wtvol
glutaraldehyd
merck
darmstadt
germani
cacodyl
buffer
merck
hohenbrunn
germani
ph
postfix
wtvol
oso
chemi
brunschwig
basel
switzerland
cacodyl
buffer
thereaft
cell
dehydr
ascend
ethanol
seri
volvol
min
embed
epon
resin
mixtur
epoxi
embed
medium
dodecenyl
succin
anhydrid
ddsa
methyl
nadic
anhydrid
mna
sigmaaldrich
buch
switzerland
ultrathin
section
nm
obtain
diamond
knive
diatom
biel
switzerland
reichertjung
ultracut
e
microtom
leica
heerbrugg
switzerland
collect
collodionco
copper
grid
electron
microscopi
scienc
hatfield
pa
usa
section
doubl
stain
wtvol
uranyl
acet
min
sigmaaldrich
steinheim
germani
wtvol
lead
citrat
min
laurylab
saint
fon
franc
ultrastain
leica
vienna
austria
examin
philip
tem
fei
eindhoven
netherland
acceler
voltag
kv
micrograph
captur
mega
view
iii
camera
use
item
softwar
olympu
soft
imag
solut
gmbh
germani
statist
evalu
test
statist
signific
differ
mean
valu
perform
use
graphpad
prism
softwar
window
graphpad
softwar
la
jolla
ca
usa
either
oneway
twoway
analysi
varianc
anova
use
follow
dunnett
multiplecomparison
test
ic
ic
calcul
nonlinear
regress
analys
leastsquar
fit
method
upper
lower
plateau
set
respect
signific
outlier
remov
perform
grubb
test
quickcalc
graphpad
drug
combin
analysi
perform
use
compusyn
comput
program
quantit
synerg
antagon
drug
combin
supplement
materi
articl
may
found
http
supplement
file
pdf
file
mb
